Median rwOS

Prior studies analyzing real-world outcomes have been limited

Baseline Cohort selection:
Advanced/metastatic NSCLC diagnosed between January 1, 2015, and March 31, 2021 outcomes of interest.

Adults (18 years or older) with a histologically or cytologically confirmed diagnosis of advanced

Patient Selection
• For the 1L+ and 2L+

Descriptive analyses were conducted using R version 3.5.2

Statistical Analysis

HER2

HER2

ERBB2

growth, proliferation, differentiation, and survival processes1

HER4) is implicated in the pathogenesis of several human cancers through participation in

after advanced/metastatic NSCLC diagnosis were excluded

1L+

2L+

Jan 2011

Mar 2022

Table 2. Baseline Clinical Characteristics for Patients With HER2 Mutation-Positive Advanced/ Metastatic NSCLC

Table 3. Baseline Clinical Characteristics for Patients With HER2 Mutation-Positive Advanced/ Metastatic NSCLC

Table 4. Treatments Used Among Patients With HER2 Mutation-Positive Advanced/Metastatic NSCLC in the 1L Setting, by Most to Least Frequent Therapy Class

Table 5. Treatments Used Among Patients With HER2 Mutation-Positive Advanced/Metastatic NSCLC in the 1L Setting, by Most to Least Frequent Therapy Class

Clinical outcomes in the 1L setting - nes5 and nES in the 2L setting are shown in Figures 4 and 5, respectively.